Related Experiment Video
Updated: Sep 15, 2026

Prediction and Validation of Gene Regulatory Elements Activated During Retinoic Acid Induced Embryonic Stem Cell Differentiation
Published on: June 21, 2016
Elevated retinoic acid receptor beta(4) protein in human breast tumor cells with nuclear and cytoplasmic localization
K M Sommer1, L I Chen, P M Treuting
1Department of Pathology, University of Washington, Seattle, WA 98195, USA.
Abstract:
The transcription factor retinoic acid receptor beta(2) (RARbeta(2)) is a potent inhibitor of breast cancer cells in vitro, and studies suggest that RARbeta expression is lost in primary breast cancer. Although RARbeta(2) is selectively down-regulated at the mRNA level in breast tumor cells, we show that expression of an RARbeta protein is elevated in five of five breast tumor cell lines relative to normal human mammary epithelial cells. Subsequent analysis identified this protein as the translation product of the human RARbeta(4) transcript. Unlike the previously characterized mouse RARbeta(4) isoform, the human RARbeta(4) retains only half of a DNA-binding domain and lacks a ligand-independent transactivation domain at its N terminus. The RARbeta(4) protein localizes to the cytoplasm and to subnuclear compartments that resemble nuclear bodies. The structure and preliminary characterizations of human RARbeta(4), coupled with the observation that its expression is greatly elevated in breast tumor cell lines, support the hypothesis that RARbeta(4) functions as a dominant-negative repressor of RAR-mediated growth suppression.
Insights
Retinoic acid receptor beta(4) (RARbeta(4)) protein, not the expected RARbeta(2), is elevated in breast tumor cells. This RARbeta(4) protein may act as a dominant-negative repressor, inhibiting normal RAR functions and promoting breast cancer growth.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Retinoic acid receptor beta(2) (RARbeta(2)) is known to inhibit breast cancer cells.
- RARbeta(2) expression is often lost in primary breast cancer.
- RARbeta(2) mRNA is down-regulated in breast tumor cells.
Purpose of the Study:
- To investigate the discrepancy between RARbeta(2) mRNA down-regulation and protein expression in breast cancer.
- To identify the specific RARbeta protein isoform expressed in breast tumor cells.
- To characterize the function of the identified RARbeta isoform in breast cancer.
Main Methods:
- Western blot analysis to detect RARbeta protein expression in breast tumor cell lines and normal mammary epithelial cells.
- RNA sequencing and protein analysis to identify the specific RARbeta transcript and its translation product.
- Immunofluorescence microscopy to determine the subcellular localization of the RARbeta protein.
- Structural analysis of the identified RARbeta protein.
Main Results:
- Expression of an RARbeta protein, identified as the human RARbeta(4) transcript's translation product, was elevated in five out of five breast tumor cell lines compared to normal cells.
- Human RARbeta(4) protein lacks a complete DNA-binding domain and a ligand-independent transactivation domain.
- RARbeta(4) protein was found in the cytoplasm and subnuclear compartments.
- Expression of RARbeta(4) is significantly elevated in breast tumor cell lines.
Conclusions:
- The elevated expression of human RARbeta(4) in breast tumor cells suggests a role in breast cancer development.
- RARbeta(4) protein's structural characteristics and localization support its function as a dominant-negative repressor.
- RARbeta(4) may interfere with RAR-mediated growth suppression pathways, contributing to uncontrolled cell proliferation in breast cancer.
More Related Videos
09:49Quantitative Measurement of Relative Retinoic Acid Levels in E8.5 Embryos and Neurosphere Cultures Using the F9 RARE-Lacz Cell-based Reporter Assay
Published on: September 6, 2016
11:12Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Related Concept Videos
The Nucleolus
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...